Synthomer extends relaxed covenants as weakness persists.

Synthomer said on Tuesday that it has secured an extension to its covenant relaxation agreement with its banking syndicate through to the end of 2026, as it navigates weaker-than-expected macroeconomic conditions and ongoing geopolitical uncertainties.

Synthomer
01 July 2025 09:49:28

Source: Sharecast

The London-listed chemicals group said the amended terms gave it additional headroom, with net debt-to-EBITDA ratio limits raised to 5.25x for December 2025, 4.5x for June 2026 and 4.25x for December 2026.

Those compared with the previous thresholds of 4.75x, 3.5x and 3.25x respectively.

Synthomer said it still expected to remain within the previously agreed 5x covenant for June, but opted to increase it slightly to 5.25x “for prudence”.

The company said the move would provide flexibility to manage the business through to an anticipated recovery in earnings over the medium term.

It said it would report its interim results for the six months to the end of June on 5 August.

At 0930 BST, shares in Synthomer were up 3.29% at 113p.

Reporting by Josh White for Sharecast.com.

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.